Kewaunee Scientific Corporation — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2016. The filing also provides unaudited fourth-quarter fiscal 2016 data; the requested “2015 Q4” period does not match the filing’s reporting period.
Business Context
Kewaunee designs, manufactures, and installs laboratory, healthcare, and technical furniture, including laboratory casework, fume hoods, workstations, countertops, sinks, and related services. Operations comprise Domestic and International segments, with manufacturing in the United States and India and sales or assembly operations in Singapore, India, and China.
- Fiscal 2016 backlog was $100.5 million, up from $90.1 million in fiscal 2015; more than 80% was expected to ship in fiscal 2017.
- Three domestic dealers represented approximately 40% of fiscal 2016 sales.
- The company had 487 domestic and 195 international full-time employees at April 30, 2016.
Financial Results and Key Metrics
| ($ in thousands, except per-share data) | Fiscal 2016 | Fiscal 2015 | Change |
|---|---|---|---|
| Net sales | $128,626 | $118,828 | +8% |
| Gross profit | $23,708 | $21,766 | +9% |
| Gross margin | 18.4% | 18.3% | +0.1 pts |
| Operating earnings | $5,698 | $5,226 | +9% |
| Net earnings attributable to Kewaunee | $3,802 | $3,529 | +8% |
| Diluted earnings per share | $1.42 | $1.33 | +7% |
| Operating cash flow | $7,271 | $2,291 | +217% |
| Capital expenditures | $2,187 | $2,568 | -15% |
- Domestic sales increased 11% to $103.0 million; international sales were approximately unchanged at $25.6 million.
- Operating expenses increased to $18.0 million, or 14.0% of sales, from $16.5 million, primarily due to $679,000 of executive retirement and replacement costs, higher incentive compensation, pension expense, and international operating costs.
- The effective tax rate was 32.4%, aided by international tax rates and state and federal tax credits.
- Cash and cash equivalents were $5.2 million; restricted cash was $1.6 million. Working capital was $30.0 million, with a current ratio of 2.4-to-1.0.
- Total borrowings were $7.6 million, including $3.6 million drawn on the revolving credit facility and $3.8 million of short-term borrowings and current debt. Stockholders’ equity was $38.2 million.
- Fiscal 2016 financing activities used $3.4 million, including $1.4 million of dividends, $1.1 million of short-term debt repayment, $888,000 paid toward the prior purchase of a subsidiary interest, and $422,000 of long-term debt repayment.
Fourth-Quarter Fiscal 2016
| ($ in thousands, except per-share data) | Q4 Fiscal 2016 | Q4 Fiscal 2015 |
|---|---|---|
| Net sales | $34,090 | $30,282 |
| Gross profit | $6,845 | $5,340 |
| Net earnings attributable to Kewaunee | $1,337 | $609 |
| Diluted earnings per share | $0.50 | $0.23 |
Material Changes and Unusual Items
- Revenue growth was driven primarily by stronger domestic dealer and distribution sales; international revenue was flat after significant growth in the prior year.
- Gross margin remained below fiscal 2014’s 19.8%, reflecting highly competitive pricing, particularly on large higher-education projects.
- Operating expenses included $679,000 of nonrecurring costs related to the retirement and replacement of a key executive. A new chief financial officer joined in November 2015, and a new manufacturing operations executive joined in May 2016.
- Inventory increased to $15.6 million from $12.7 million, while receivables declined to $27.8 million from $29.1 million.
- The company changed from a fully insured healthcare program to a self-insured program effective January 1, 2016, subject to stop-loss coverage.
- The defined benefit pension plan remained underfunded by $5.3 million. The company expected to contribute $555,000 in fiscal 2017, compared with $64,000 contributed in fiscal 2016.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of April 30, 2016. The independent auditor issued an unqualified opinion on the consolidated financial statements.
Guidance, Outlook, Risks, and Contingencies
- Management expected fiscal 2017 capital expenditures of approximately $3.0 million, primarily for manufacturing equipment, funded mainly from operations and supplemented by revolver borrowings if needed.
- Management stated that operating cash flow, the revolving facility, and equipment leases should be sufficient to support ongoing requirements through fiscal 2017.
- The $20 million revolving credit facility was extended to May 1, 2018. At April 30, 2016, $12.2 million remained available after advances and letters of credit.
- The company was in compliance with all financial covenants at year-end and had no off-balance-sheet arrangements.
- Key risks include competitive bidding and pricing pressure, raw-material and energy-cost inflation under fixed-price contracts, construction delays and customer rescheduling, dependence on three major dealers, international political and currency risks, economic weakness in laboratory construction, and the ability to generate sufficient operating cash flow.
- Contractual obligations totaled $7.2 million, including $3.5 million of operating leases and $3.8 million of long-term debt payments.
- Pending ordinary-course legal claims and proceedings were not expected by management to have a material adverse effect.
- The company planned to adopt new accounting standards for revenue recognition in fiscal 2019, inventory in fiscal 2018, leases in fiscal 2020, and stock compensation in fiscal 2018; the effects of several standards had not yet been determined.
Investor Verification Checklist
- Verify whether backlog converts to revenue as expected, particularly the portion scheduled for fiscal 2017.
- Assess sustainability of the 18.4% gross margin amid competitive pricing and fixed-price project commitments.
- Review customer concentration, including the approximately 40% of sales generated by three domestic dealers.
- Monitor inventory growth, receivables collection, retention amounts, and operating cash flow conversion.
- Confirm revolver availability, letters of credit, debt amortization, interest-rate exposure, and ongoing covenant compliance.
- Evaluate pension funding requirements and the potential volatility of pension expense and other comprehensive income.
- Review the impact of the new self-insured healthcare program and related claims reserves.
- Confirm the eventual effects of the pending accounting standards, especially revenue recognition and lease capitalization.